- Home
- COAG vs GHRS Comparison
COAG vs GHRS Comparison
Compare COAG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COAG | GHRS |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | COAG | GHRS |
|---|---|---|
| Price | $30.17 | $18.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $62.67 | $42.89 |
| AVG Volume (30 Days) | ★ 515.7K | 299.1K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.38 | $12.04 |
| 52 Week High | $55.42 | $31.44 |
Technical Indicators
Market Signals| Indicator | COAG | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 22.04 |
| Support Level | $28.46 | $13.58 |
| Resistance Level | $33.93 | $22.88 |
| Average True Range (ATR) | 2.32 | 1.19 |
| MACD | 0.43 | -0.33 |
| Stochastic Oscillator | 43.46 | 2.31 |
Price Performance
Historical ComparisonAbout COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.